heart failure

Vesnarinone (Arkin) (INN) is a mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. It also suppresses cell proliferation and induces apoptosis by inducing the expression of p21, an inhibitor of cyclin-dependent kinase activity in p53-mediated cell cycle arrest.

Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM and is a component of the heart failure medicine LCZ696.

Dobutamine hydrochloride (Dobutamine (hydrochloride)) is a catecholamine that acts as a β-adrenergic receptor agonist with potent positive inotropic effects.

Furosemide is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used for edema and chronic renal insufficiency.

Anti-Heart Failure Agent 1 is an orally available compound suitable for treating heart failure without causing vomiting, nausea, or restlessness.

Candoxatril (UK 79300) is an orally active neutral peptide endonuclease (NEP, EC 3.4.24.11) inhibitor that improves exercise capacity in patients with chronic heart failure undergoing angiotensin-converting enzyme inhibition.

Mitiperstat is a potent myeloperoxidase (MPO) inhibitor that is effective in preventing cardiovascular diseases such as heart failure and coronary artery disease.

AZD5462 is a potent orally available relaxin receptor RXFP1 agonist for the study of heart failure and cancer.

Bucindolol Formatel is a blocker of β1-adrenergic receptor. Bucindolol exhibits intrinsic sympathomimetic activity. Bucindolol can be used in the research of heart failure.

OR-1896 is the active metabolite of Levosimendan, a highly specific phosphodiesterase (PDE III) inhibitor, a vasodilator with partial anti-inflammatory properties that produces vasodilation in different types of blood vessels through activation of ATP-sensitive (KATP) and other potassium channels.OR-1896 can be used to study heart failure and vascular dysfunction. OR-1896 can be used to study heart failure and vascular dysfunction.

(2R,3S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide is an Apelin receptor agonist with an EC50 for Apelin receptors of 0.012 µM.(2R,3S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5- methylpyrimidin-2-yl)butane-2-sulfonamide is used in the treatment of heart failure, atherosclerosis, obesity, diabetes mellitus, amyotrophic lateral sclerosis, coronary artery disease, hypertension, stroke and myocardial infarction.

PD-118057 is a potent ether associated (hERG) potassium channel activator that shows no activity against hERG. PD-118057 inhibits the excitability of the membrane by activating the hERG channel. PD-118057 is a potential compound for the treatment of delayed repolarization in inherited or acquired long QT syndrome and congestive heart failure.

Tonapofylline is an orally active and selective antagonist of the A1 adenosine receptor (Ki: 7.4 nM for human A1). Tonapofylline can be used in studies about heart failure.

(±)-Prenalterol (H 80 62) is a new cardioselective positive inotropic compound that is an agonist of beta-2- and beta-1-adrenergic receptors and can be used to study chronic congestive heart failure.

(Rac)-Daglutril (SLV 306 acetic acid) is the racemate form of Daglutril. Daglutril is an orally active, mixed neutral endopeptidase endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

Imazodan hydrochloride (CI-914 HCl) is a potent and selective type III phosphodiesterase inhibitor used in the treatment of chronic congestive heart failure.

Pomisartan (BIBR-363) is a small molecule angiotensin type 1 receptor (AT1R) antagonist that is used in the treatment of cardiovascular disease, studying heart failure and hypertensio

Pomisartan 2HCl (BIBR363 2HCL) is a small molecule AT1R antagonist used to study heart failure and hypertension.

Edonentan is A potent endothelin A (ETA) receptor antagonist that can be used to study heart failure.

Nanterinone (UK 61260), an orally available partial phosphodiesterase inhibitor, is a novel positive inotropic and balanced vasodilator compound.Nanterinone, when administered orally, results in significant improvements in acute haemodynamics, which may depend on pre-existing left ventricular filling pressures.Nanterinone is a novel positive inotropic and balanced vasodilator that has demonstrated acute hemodynamic effects in patients with mild to moderate heart failure.

(Rac)-Naxifylline may be used to study congestive heart failure.

Nolomirole is a dopamine receptor agonist that reduces symptoms of congestive heart failure caused by monoclinine.

Nolomirole HCl (CHF 1035) is a novel selective dopamine agonist with oral activity and inhibitory effects on norepinephrine release, which can be used to study mild chronic heart failure.

Vesnarinone HCl (OPC-8212 HCl) is an orally active phosphodiesterase 3 (PDE3) inhibitor.Vesnarinone HCl modulates calcium and potassium ions, increasing calcium flux and decreasing potassium flux.Vesnarinone HCl is a new positive inotropic compound that enhances myocardial contractility and can be be used in heart failure studies.